Skip to main content

Advertisement

Table 2 Expression of p-MET and its correlation with clinicopathological parameters in 121 cases

From: Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma

Parameters Grouping n p-MET [case (%)] χ2test
Positive Negative χ2value P value
Age (year) <60 40 24(60.0) 16(40.0) 0.766 0.862
≥60 81 48(59.3) 33(40.7)   
Gender Male 77 48(62.3) 29(37.7) 1.976 0.187
Female 44 24(54.5) 20(45.5)   
Tumor diameter (cm) <5 48 33(68.8) 15(31.3) 1.138 0.236
≥5 73 39(53.4) 34(46.6)   
Location of tumor Cardia, fundus 20 15(75.0) 5(25.0) 10.252 0.009
Body 37 27(73.0) 10(27.0)   
Pylorus, antrum 64 30(46.9) 34(53.1)   
Lauren classification Intestinal 84 55(65.5) 29(34.5) 0.924 0.186
Diffuse 37 17(45.9) 20(54.1)   
Histological type Grade 1 25 13(52.0) 12(48.0) 0.192 0.741
Grade 2 47 28(59.6) 19(40.4)   
Grade 3 49 31(63.3) 18(36.7)   
Invasion depth T1 18 9(50.0) 9(50.0) 1.996 0.156
T2 32 18(56.3) 14(43.8)   
T3 30 19(63.3) 11(36.7)   
T4 41 26(63.4) 15(36.6)   
Metastatic lymph node ratio <35% 60 30(50.0) 30(50.0) 8.556 0.007
≥35% 61 42(68.9) 19(31.1)   
Involving lymph node station N0 43 20(46.5) 23(53.5) 9.651 0.042
N1 41 27(65.9) 14(34.1)   
N2 26 16(61.5) 10(38.5)   
N3 11 9(81.8) 2(18.2)   
TNM stages Ia 16 8(50.0) 8(50.0) 10.887 0.016
Ib 17 8(47.1) 9(52.9)   
II 20 13(65.0) 7(35.0)   
IIIa 20 13(65.0) 7(35.0)   
IIIb 22 14(63.6) 8(36.4)   
IV 26 16(61.5) 10/38.5)   
Survival (month) <20 75 52(69.3) 23(30.7) 10.006 0.004
≥20 46 20/(43.5) 26/(56.5)